These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 17606473

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.
    Bushe C, Yeomans D, Floyd T, Smith SM.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):56-62. PubMed ID: 18477621
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A review of the association between antipsychotic use and hyperprolactinaemia.
    Bushe C, Shaw M, Peveler RC.
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):46-55. PubMed ID: 18477620
    [Abstract] [Full Text] [Related]

  • 5. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
    Lai YC, Chiou CC, Chen CH, Huang MC.
    J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M, Avital A, Derevenski A, Berstein S, Sandbank S, Weizman A.
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
    Lawford BR, Barnes M, Connor JP, Heslop K, Nyst P, Young RM.
    J Psychopharmacol; 2012 Feb; 26(2):324-9. PubMed ID: 21262859
    [Abstract] [Full Text] [Related]

  • 10. Atypical antipsychotics and pituitary neoplasms in the WHO database.
    Doraiswamy PM, Schott G, Star K, Edwards R, Mueller-Oerlinghausen B.
    Psychopharmacol Bull; 2007 Feb; 40(1):74-6. PubMed ID: 17285098
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
    Kinon BJ, Gilmore JA, Liu H, Halbreich UM.
    Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
    Byerly M, Suppes T, Tran QV, Baker RA.
    J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM, Wieck A.
    Drugs; 2004 Dec; 64(20):2291-314. PubMed ID: 15456328
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports.
    Haddad PM, Hellewell JS, Wieck A.
    J Psychopharmacol; 2001 Dec; 15(4):293-5. PubMed ID: 11769824
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
    Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):92-6. PubMed ID: 16938372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.